340B Contract Pharmacy Audits Double: HRSA Targets Compliance Gaps at FQHCs
Issue
HRSA has doubled 340B program audits targeting contract pharmacy arrangements, with 47 covered entities under review in Q1 2026. Common violations include duplicate discounts, inadequate patient eligibility verification, and missing contract pharmacy agreements.
FQHCs operating 340B programs must demonstrate real-time eligibility checks, split-billing compliance, and complete audit trails for every 340B transaction. Non-compliance can result in program repayment and suspension.
Key points
- HRSA doubled 340B audits: 47 covered entities under review in Q1 2026
- Common violations: duplicate discounts, inadequate eligibility verification, missing pharmacy agreements
- Non-compliance: program repayment and suspension
- Action: demonstrate real-time eligibility checks, split-billing compliance, complete audit trails
Sources for this story
HRSA Office of Pharmacy AffairsSources for your board packet
This story's source plus 4 related stories and their sources, ready to print for your team or board.
Free. Unlocking the packet subscribes you to Intel Brief. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.
Part of
- 340B drug pricing
HRSA audits and repayment
FQHC Talent. (2026, February 15). 340B Contract Pharmacy Audits Double: HRSA Targets Compliance Gaps at FQHCs. Source: HRSA Office of Pharmacy Affairs. Retrieved October 6, 2026, from https://www.fqhctalent.com/intel/340b-audit-wave-contract-pharmacy-2026
More in Risk & Compliance
Sep 29
HHS civil rights office says when states can use substance use records
Sep 25
CMS and 37 states pledge to judge Medicaid by health outcomes
Sep 24
Geiger Gibson review finds health centers expect a heavy work-rule frailty burden
Sep 24
CMS seeks input on Part D pharmacy contract terms, including 340B claims